Anmelden Kostenlos registrieren

Telesis Bio Inc leerverkaufte Aktien zu allen Aktien

Was ist das leerverkaufte Aktien zu allen Aktien von Telesis Bio Inc?

leerverkaufte Aktien zu allen Aktien von Telesis Bio Inc ist 12.10

Was ist die Definition von leerverkaufte Aktien zu allen Aktien?



Das Leerverkauf-Verhältnis ist die Anzahl der leervekauften Aktien geteilt durch das durchschnittliche tägliche Volumen.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

leerverkaufte Aktien zu allen Aktien von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Telesis Bio Inc

Was macht Telesis Bio Inc?

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.

Unternehmen mit leerverkaufte aktien zu allen aktien ähnlich Telesis Bio Inc